Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P46527

UPID:
CDN1B_HUMAN

ALTERNATIVE NAMES:
Cyclin-dependent kinase inhibitor p27; p27Kip1

ALTERNATIVE UPACC:
P46527; Q16307; Q5U0H2; Q9BUS6

BACKGROUND:
The Cyclin-dependent kinase inhibitor 1B, known alternatively as p27Kip1, is a crucial regulator of cell cycle progression. It selectively inhibits CDK2 bound to cyclin A, facilitating G1 arrest, and plays a role in the assembly and function of CCND1-CDK4 complexes. Its activity varies based on phosphorylation state and stoichiometry.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in Multiple endocrine neoplasia 4, a syndrome with phenotypic overlaps of MEN1 and MEN2, Cyclin-dependent kinase inhibitor 1B represents a significant target for drug discovery. Exploring its function further could lead to groundbreaking therapeutic interventions for thyroid cancers and possibly other cell cycle-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.